09.12.2022 • NewsNouryon

Nouryon Buys Singapore Alkoxylation Plant

Nouryon has bought an alkoxylation plant in Singapore. The company said the plant on Jurong Island will enhance its ability to serve growing regional demand in key end-markets, such as agriculture and food, home and personal care, natural resources, and paints and coatings.

Nouryon has purchased an alkoxylation plant in Singapore, boosting its manufacturing footprint in Southeast Asia. The purchase price was not disclosed, nor was the seller’s identity.

The company said the plant on Jurong Island will enhance its ability to serve growing regional customer demand in key end-markets, such as agriculture and food, home and personal care, natural resources, and paints and coatings.

© chitsanupong – stock.adobe.com
© chitsanupong – stock.adobe.com

“This acquisition of a specialty surfactant alkoxylation plant in Singapore will enhance our ability to serve fast-growing end-markets in Asia Pacific and adds to our existing alkoxylation network of manufacturing facilities in China, Sweden and the US,” said Larry Ryan, executive vice president and president, performance formulations and the Americas.

Ryan added that Nouryon will continue to look at strategic opportunities to expand its manufacturing footprint and product offering.

Author: Elaine Burridge, Freelance Journalist

Company

Logo:

Nouryon

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.